Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation (TPD) and Ubiquitin-Proteasome System (UPS) Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Ubiquitin-involved drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Ubiquitin (Wild-Type & Mutants like K48R, K63R) High purity (>95%), Mass Spectrometry Verified, Endotoxin Controlled. |
View Ubiquitin Products |
| Gene Delivery | UBB Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression. |
View UBB Products |
| Benchmark Ab | Anti-Ubiquitin Recombinant Antibody High-affinity positive control for Western Blot and Immunoprecipitation. |
View Ubiquitin Products |
| Validator | UBB siRNA Set For knock-down validation in functional assays. |
View UBB Products |
| Related Target A | Cereblon (CRBN) Key E3 ligase substrate receptor for PROTAC and Molecular Glue recruitment. |
View CRBN Products |
| Related Target B | VHL (Von Hippel-Lindau) E3 ligase component widely utilized in bifunctional degrader designs. |
View VHL Products |
| Related Target C | USP7 (Ubiquitin Specific Peptidase 7) Deubiquitinating enzyme (DUB) target for oncology and immunology. |
View USP7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ubiquitin Linkage Specificity (K48 vs. K63) | Linkage-specific mutant proteins (K48R, K63R) strictly verified by intact Mass Spectrometry. |
| E3 Ligase Off-Target Screening | Homolog panel of E3 ligase complexes (CRBN-DDB1, VHL-Elongin B/C) with precise stoichiometry. |
| Lack of Controls | Sequence-verified clinical biosimilar antibodies and recombinant control proteins available. |
| False Positives in HTS | Validated siRNA sets included for target-specific knockdown verification. |
Live Ubiquitin (UBB) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Ubiquitin-system therapeutics is intensifying, with major players shifting focus from traditional inhibitors to Targeted Protein Degradation (TPD) modalities like PROTACs, Molecular Glues, and Deubiquitinase (DUB) inhibitors. As first-generation degraders targeting AR and ER reach pivotal clinical phases, the next wave of R&D is targeting difficult-to-drug oncology drivers, neurodegenerative aggregates, and inflammatory mediators by hijacking the cellular ubiquitin machinery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs | Arvinas, Dialectic Therapeutics, Kymera Therapeutics | Prostate Cancer, Breast Cancer, Hematological Malignancies | Ternary Complex Formation Assay (Requires high-purity E3 ligases and target proteins) |
| Molecular Glues | Monte Rosa Therapeutics, Bristol Myers Squibb | Solid Tumors, Inflammatory Diseases | Co-immunoprecipitation and structural validation (Requires sequence-verified recombinant proteins) |
| DUB Inhibitors | Mission Therapeutics, Ubiquigent | Neurodegenerative Disorders, Oncology | Deubiquitinating activity assays (Requires high-purity mono- and poly-ubiquitin chains) |